Fintel reports that on December 2, 2025, Stifel maintained coverage of Janux Therapeutics (NasdaqGM:JANX) with a Buy recommendation.
Analyst Price Forecast Suggests 128.77% Upside
As of November 17, 2025, the average one-year price target for Janux Therapeutics is $77.76/share. The forecasts range from a low of $25.25 to a high of $210.00. The average price target represents an increase of 128.77% from its latest reported closing price of $33.99 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Janux Therapeutics is 2MM, a decrease of 83.00%. The projected annual non-GAAP EPS is -1.83.
What is the Fund Sentiment?
There are 398 funds or institutions reporting positions in Janux Therapeutics. This is an decrease of 22 owner(s) or 5.24% in the last quarter. Average portfolio weight of all funds dedicated to JANX is 0.15%, an increase of 10.67%. Total shares owned by institutions decreased in the last three months by 0.67% to 71,391K shares. 
The put/call ratio of JANX is 0.36, indicating a bullish outlook.
What are Other Shareholders Doing?
Ra Capital Management holds 11,190K shares representing 18.60% ownership of the company. No change in the last quarter.
Janus Henderson Group holds 4,701K shares representing 7.82% ownership of the company. In its prior filing, the firm reported owning 4,460K shares , representing an increase of 5.12%. The firm increased its portfolio allocation in JANX by 3.94% over the last quarter.
Paradigm Biocapital Advisors holds 2,920K shares representing 4.86% ownership of the company. No change in the last quarter.
Adage Capital Partners Gp, L.l.c. holds 2,775K shares representing 4.61% ownership of the company. In its prior filing, the firm reported owning 2,525K shares , representing an increase of 9.01%. The firm increased its portfolio allocation in JANX by 9.29% over the last quarter.
Orbimed Advisors holds 1,766K shares representing 2.94% ownership of the company. In its prior filing, the firm reported owning 1,210K shares , representing an increase of 31.47%. The firm increased its portfolio allocation in JANX by 45.12% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
